Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis

Cancer Cell

Volumn 30, Issue 6, 2016, Pages 909-924

  Kettner, Nicole M ^a   Voicu, Horatio ^a   Finegold, Milton J ^a   Coarfa, Cristian ^a   Sreekumar, Arun ^a   Putluri, Nagireddy ^a   Katchy, Chinenye A ^a   Lee, Choogon ^b   Moore, David D ^a   Fu, Loning ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

cholestasis; chronic circadian disruption; constitutive androstane receptor (CAR); farnesoid X receptor (FXR); fibrosis; hepatocarcinogenesis; non alcoholic fatty liver disease; non alcoholic steatohepatitis; social jet lag; sympathetic dysfunction

Indexed keywords

BILE ACID; CHOLESTEROL; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CIRCADIAN RHYTHM; CONTROLLED STUDY; DISEASE COURSE; GENE CONTROL; GENE OVEREXPRESSION; INTRAHEPATIC CHOLESTASIS; JET LAG; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER METABOLISM; METABOLIC SYNDROME X; MOUSE; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE; XENOBIOTIC METABOLISM; ANIMAL; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HOMEOSTASIS; HUMAN; LIVER; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; METABOLOME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CIRCADIAN CLOCKS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLOME; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 85004115511     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.10.007     Document Type: Article

References (63)

1. Anand, P., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Tharakan, S.T., Lai, O.S., Sung, B., Aggarwal, B.B., Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 25 (2008), 2097–2116.
2. Audard, V., Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher-Lavenu, M.C., Perret, C., Cavard, C., Terris, B., Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J. Pathol. 212 (2007), 345–352.
3. Bass, J., Takahashi, J.S., Circadian integration of metabolism and energetics. Science 330 (2010), 1349–1354.
4. Diwan, B.A., Rice, J.M., Ward, J.M., Strain-dependent effects of phenobarbital on liver tumor promotion in inbred mice. Prog. Clin. Biol. Res. 331 (1990), 69–83.
5. Dong, B., Lee, J.S., Park, Y.Y., Yang, F., Xu, G., Huang, W., Finegold, M.J., Moore, D.D., Activating CAR and beta-catenin induces uncontrolled liver growth and tumorigenesis. Nat. Commun., 6, 2015, 5944.
6. Drinkwater, N.R., Ginsler, J.J., Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis 7 (1986), 1701–1707.
7. El-Serag, H.B., Hepatocellular carcinoma. N. Engl. J. Med. 365 (2011), 1118–1127.
8. Fu, L., Kettner, N.M., The circadian clock in cancer development and therapy. Prog. Mol. Biol. Trans. Sci. 119 (2013), 221–282.
9. Fu, L., Pelicano, H., Liu, J., Huang, P., Lee, C., The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 (2002), 41–50.
10. Furness, J.B., The organisation of the autonomic nervous system: peripheral connections. Auton. Neurosci. 130 (2006), 1–5.
11. Gachon, F., Olela, F.F., Schaad, O., Descombes, P., Schibler, U., The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4 (2006), 25–36.
12. Goodwin, B., Jones, S.A., Price, R.R., Watson, M.A., McKee, D.D., Moore, L.B., Galardi, C., Wilson, J.G., Lewis, M.C., Roth, M.E., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6 (2000), 517–526.
13. Guo, G.L., Lambert, G., Negishi, M., Ward, J.M., Brewer, H.B. Jr., Kliewer, S.A., Gonzalez, F.J., Sinal, C.J., Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278 (2003), 45062–45071.
14. Guzman, G., Brunt, E.M., Petrovic, L.M., Chejfec, G., Layden, T.J., Cotler, S.J., Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch. Pathol. Lab. Med. 132 (2008), 1761–1766.
15. Hashimoto, E., Yatsuji, S., Tobari, M., Taniai, M., Torii, N., Tokushige, K., Shiratori, K., Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 44:Suppl 19 (2009), 89–95.
16. Hirschfield, G.M., Mason, A., Luketic, V., Lindor, K., Gordon, S.C., Mayo, M., Kowdley, K.V., Vincent, C., Bodhenheimer, H.C. Jr., Pares, A., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148 (2015), 751–761.e8.
17. Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D.Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M.J., Lerner, J., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359 (2008), 1995–2004.
18. Hosono, S., Chou, M.J., Lee, C.S., Shih, C., Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene 8 (1993), 491–496.
19. Hu, L.Y., Chen, P.M., Hu, Y.W., Shen, C.C., Perng, C.L., Su, T.P., Yen, S.H., Tzeng, C.H., Chiou, T.J., Yeh, C.M., et al. The risk of cancer among patients with sleep disturbance: a nationwide retrospective study in Taiwan. Ann. Epidemiol. 23 (2013), 757–761.
20. Huang, W., Zhang, J., Wei, P., Schrader, W.T., Moore, D.D., Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. Mol. Endocrinol. 18 (2004), 2402–2408.
21. Huang, W., Zhang, J., Washington, M., Liu, J., Parant, J.M., Lozano, G., Moore, D.D., Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol. 19 (2005), 1646–1653.
22. Huang, Q., Lin, B., Liu, H., Ma, X., Mo, F., Yu, W., Li, L., Li, H., Tian, T., Wu, D., et al. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One, 6, 2011, e26168.
23. Huang, Y., Chen, H.C., Chiang, C.W., Yeh, C.T., Chen, S.J., Chou, C.K., Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells. Nucleic Acids Res. 40 (2012), 10478–10493.
24. Kao, C.H., Sun, L.M., Liang, J.A., Chang, S.N., Sung, F.C., Muo, C.H., Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo. Clin. Proc. 87 (2012), 430–436.
25. Kettner, N.M., Katchy, C.A., Fu, L., Circadian gene variants in cancer. Ann. Med. 46 (2014), 208–220.
26. Kettner, N.M., Mayo, S.A., Hua, J., Lee, C., Moore, D.D., Fu, L., Circadian dysfunction induces leptin resistance in mice. Cell Metab. 22 (2015), 448–459.
27. Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J.M., Gonzalez, F.J., Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28 (2007), 940–946.
28. Kim, C.W., Yun, K.E., Jung, H.S., Chang, Y., Choi, E.S., Kwon, M.J., Lee, E.H., Woo, E.J., Kim, N.H., Shin, H., Ryu, S., Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. J. Hepatol. 59 (2013), 351–357.
29. Koike, N., Yoo, S.H., Huang, H.C., Kumar, V., Lee, C., Kim, T.K., Takahashi, J.S., Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science 338 (2012), 349–354.
30. Kunstyr, I., Leuenberger, H.G., Gerontological data of C57BL/6J mice. I. Sex differences in survival curves. J. Gerontol. 30 (1975), 157–162.
31. Lamia, K.A., Storch, K.F., Weitz, C.J., Physiological significance of a peripheral tissue circadian clock. Proc. Natl. Acad. Sci. USA 105 (2008), 15172–15177.
32. Lee, J.S., Heo, J., Libbrecht, L., Chu, I.S., Kaposi-Novak, P., Calvisi, D.F., Mikaelyan, A., Roberts, L.R., Demetris, A.J., Sun, Z., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12 (2006), 410–416.
33. Lee, S., Donehower, L.A., Herron, A.J., Moore, D.D., Fu, L., Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One, 5, 2010, e10995.
34. Loeppen, S., Schneider, D., Gaunitz, F., Gebhardt, R., Kurek, R., Buchmann, A., Schwarz, M., Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res. 62 (2002), 5685–5688.
35. Lopez-Velazquez, J.A., Carrillo-Cordova, L.D., Chavez-Tapia, N.C., Uribe, M., Mendez-Sanchez, N., Nuclear receptors in nonalcoholic fatty liver disease. J. Lipids, 2012, 2012, 139875.
36. Lu, T.T., Makishima, M., Repa, J.J., Schoonjans, K., Kerr, T.A., Auwerx, J., Mangelsdorf, D.J., Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6 (2000), 507–515.
37. Ma, K., Xiao, R., Tseng, H.T., Shan, L., Fu, L., Moore, D.D., Circadian dysregulation disrupts bile acid homeostasis. PLoS One, 4, 2009, e6843.
38. Magnon, C., Hall, S.J., Lin, J., Xue, X., Gerber, L., Freedland, S.J., Frenette, P.S., Autonomic nerve development contributes to prostate cancer progression. Science, 341, 2013, 1236361.
39. Michelotti, G.A., Machado, M.V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 656–665.
40. Mohawk, J.A., Green, C.B., Takahashi, J.S., Central and peripheral circadian clocks in mammals. Annu. Rev. Neurosci. 35 (2012), 445–462.
41. Nose, H., Imazeki, F., Ohto, M., Omata, M., p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer 72 (1993), 355–360.
42. Perez, M.J., Briz, O., Bile-acid-induced cell injury and protection. World J. Gastroenterol. 15 (2009), 1677–1689.
43. Review, T., LaBrecque, D.R., Abbas, Z., Anania, F., Ferenci, P., Khan, A.G., Goh, K.L., Hamid, S.S., Isakov, V., Lizarzabal, M., et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 48 (2014), 467–473.
44. Ripperger, J.A., Schibler, U., Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat. Genet. 38 (2006), 369–374.
45. Roenneberg, T., Chronobiology: the human sleep project. Nature 498 (2013), 427–428.
46. Roenneberg, T., Allebrandt, K.V., Merrow, M., Vetter, C., Social jetlag and obesity. Curr. Biol. 22 (2012), 939–943.
47. Siegel, A.B., Zhu, A.X., Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115 (2009), 5651–5661.
48. Tentolouris, N., Liatis, S., Katsilambros, N., Sympathetic system activity in obesity and metabolic syndrome. Ann. N. Y. Acad. Sci. 1083 (2006), 129–152.
49. Tokushige, K., Hashimoto, E., Horie, Y., Taniai, M., Higuchi, S., Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J. Gastroenterol. 46 (2011), 1230–1237.
50. Villanueva, A., Hernandez-Gea, V., Llovet, J.M., Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 34–42.
51. Voigt, R.M., Forsyth, C.B., Green, S.J., Mutlu, E., Engen, P., Vitaterna, M.H., Turek, F.W., Keshavarzian, A., Circadian disorganization alters intestinal microbiota. PLoS One, 9, 2014, e97500.
52. Wang, Y.D., Chen, W.D., Wang, M., Yu, D., Forman, B.M., Huang, W., Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48 (2008), 1632–1643.
53. Wang, S.N., Lee, K.T., Ker, C.G., Leptin in hepatocellular carcinoma. World J. Gastroenterol. 16 (2010), 5801–5809.
54. Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
55. Watanabe, M., Houten, S.M., Wang, L., Moschetta, A., Mangelsdorf, D.J., Heyman, R.A., Moore, D.D., Auwerx, J., Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113 (2004), 1408–1418.
56. Woo, H.G., Park, E.S., Cheon, J.H., Kim, J.H., Lee, J.S., Park, B.J., Kim, W., Park, S.C., Chung, Y.J., Kim, B.G., et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res. 14 (2008), 2056–2064.
57. Yamamoto, Y., Moore, R., Goldsworthy, T.L., Negishi, M., Maronpot, R.R., The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 64 (2004), 7197–7200.
58. Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D.D., Huang, W., Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67 (2007), 863–867.
59. Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., Shima, T., Kanbara, Y., Saibara, T., Mori, T., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 9 (2011), 428–433 quiz e450.
60. Ye, Q.H., Qin, L.X., Forgues, M., He, P., Kim, J.W., Peng, A.C., Simon, R., Li, Y., Robles, A.I., Chen, Y., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 9 (2003), 416–423.
61. Zhang, J., Huang, W., Qatanani, M., Evans, R.M., Moore, D.D., The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279 (2004), 49517–49522.
62. Zimberg, I.Z., Fernandes Junior, S.A., Crispim, C.A., Tufik, S., de Mello, M.T., Metabolic impact of shift work. Work 41:Suppl 1 (2012), 4376–4383.
63. Zucman-Rossi, J., Villanueva, A., Nault, J.C., Llovet, J.M., Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149 (2015), 1226–1239.e4.